Comparison of the Recombinant Versus Highly-Purified, Urinary Follicle-Stimulating Hormone (r-FSH vs. HP-uFSH) in the Polycystic Ovary Syndrom Patients who had Antagonist Cycle with In Vitro Fertilization- mbryo Transfer

Abstract

A AB BS S T TR RA AC CT T O Ob b j je ec c t ti i v ve es s: : Although there are a number of studies on the costs and efficacy of the drugs which are used in in vitro fertilization (IVF), the data obtained in antagonist cycles of polycystic ovary syndrome (PCOS) cases are still controversial. The aim of the study was to evaluate follicular development, pregnancy outcome and cost-effectiveness comparing r-FSH and HP-u FSH in antagonist cycles of PCOS cases. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : A total of 102 patients were included in the study. Patients were treated using the same stimulation protocol. r-FSH (n= 54) or HP-u FSH (n= 48) were given according to the clinician's choice and the patient's preference. R Re es su ul lt ts s: : r-FSH treatment required significantly less amount to induce follicular development and resulted in higher plasma levels of estradiol on the day of human chorionic gonadotropin (hCG) injection. Although pregnancy rate in the r FSH group was higher than HP u FSH group (40.7% vs. 33.3%), the difference was not statistically significant. Total FSH dose was significantly lower in r FSH group comparet to HP-uFSH (1396.3 ± 131.6 iu vs.1820.14 ± 174.6 iu). C Co on nc cl lu us si io on n: : r-FSH is more efficient than HP-u FSH in terms of total FSH dose. The Follicular development and endometrial thickness on the day of hCG were better in the r-FSH group, however these differences were not statistically significant. Although r-FSH is more expensive, the final treatment cost with r-FSH per pregnancy was slightly lower although this difference was not statistically significant. K Ke ey y W Wo or rd ds s: : Follicle stimulating hormone; polycystic ovary syndrome; pregnancy Ö ÖZ ZE ET T A Am ma aç ç: : İn vitro fertilizasyonun (İVF) ma li ye ti ve kul la nı lan ilaç la rın et kin li ği hak kın da da ha ön ce ya yın lan mış bir çok ça lış ma lar ol ma sı na rağ men, an ta go nist sik lus ugu la nan po li kistik overli (PKO) has ta lar dan el de edi len bil gi ler ha len tar tış ma lı dır. Bu ça lış ma nın ama cı r FSH ve HP-u FSH'nin an ta go nist sik lus ya pı lan PKO'lu has ta lar da ki fol li kül ge li şi mi, ge be lik sonuç la rı ve ma li ye te et ki si ni de ğer len dir mek ti. G Ge e r re eç ç v ve e Y Yö ön n t te em m l le er r: : Top lam 102 has ta ça lış maya da hil edil di. Has ta lar ay nı sti mü las yon yön te miy le te da vi edil di. r FSH (n= 54) ve HP-uFSH n= 48) kli nis ye nin se çi mi ve has ta nın ter ci hi ne gö re ve ril di. B Bu ul l g gu u l la ar r: : r FSH te da vi si fol li kü ler ge li şi mi in dük le mek için da ha az ilaç ge rek tir di ve hu man ko ri yo nik go na dot ro pin (hCG) injek si yon gü nün de da ha yük sek plaz ma es tra di ol dü zey le riy le so nuç lan dı. Ge be lik ora nı r FSH gru bun da HP-uFSH gru bu na gö re da ha yük sek ol ma sı na rağ men (%40.7'ye kar şı %33.3), arada ki fark is ta tis tik sel ola rak an lam lı de ğil di. To plam FSH do zu r FSH gru bun da HP-uFSH'tan an lam lı de re ce de da ha dü şük tü (1396.3 ± 131....